A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate safety and effectiveness of medication MK-2140 in patients with Diffuse Large B Cell Lymphoma who failed prior therapies.
- Conditions
- Diffuse Large B Cell Lymphoma (a type of non-Hodgkin’s lymphoma, in patients who failed prior therapies)MedDRA version: 21.0Level: LLTClassification code: 10012820Term: Diffuse large B-cell lymphoma NOS Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2022-501243-33-00
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 129
Has relapsed or refractory (rr) diffuse large B-cell lymphoma diffused large B-cell lymphoma (DLBCL); has progressed after at least 2 lines of prior therapy; and has progressed after auto- stem cell transplant (SCT) or are auto-SCT ineligible. Must have received prior multiagent regimen that includes an alkylating agent. anthracycline, and anti-CD20 (cluster of differentiation 20) monoclonal antibody., Has histologically confirmed diagnosis of DLBCL., Has radiographically measurable DLBCL per the Lugano Response Criteria, Should either be post- chimeric antigen receptor T cell therapy (CAR-T) failure or ineligible for CAR-T (for any reason), Life expectancy of at least 3 months, Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessed within 7 days before time of enrollment, Has adequate organ function
Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL), Has received prior systemic anticancer therapy, including investigational agents within 4 weeks prior to the first dose of study intervention, Has received prior radiotherapy within 28 days of start of study intervention. Participants must have recovered from all radiation-related toxicities, Has ongoing corticosteroid therapy (exceeding 30 mg daily of prednisone equivalent), Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention, Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention, Has known active central nervous system (CNS) lymphoma involvement or active CNS involvement by lymphoma, Has an active infection requiring systemic therapy, Has a known history of human immunodeficiency virus (HIV) infection, Has a known history of hepatitis B or known active hepatitis C virus (HCV), Has undergone solid organ transplant at any time, Has a history of any clinically significant cardiovascular conditions within 6 months of screening or serious cardiac arrhythmia requiring medication, Has known history of liver cirrhosis, Has pericardial effusion or clinically significant pleural effusion, Has ongoing Grade >1 peripheral neuropathy, Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years, Transformed DLBCL from indolent lymphoma, In participants with prior allo-SCT, acute graft versus host disease (GVHD) or ongoing evidence of chronic GVHD
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To evaluate zilovertamab vedotin with respect to objective response rate per Lugano Response Criteria as assessed by Blinded Independent Central Review (BICR);Secondary Objective: To evaluate zilovertamab vedotin with respect to duration of response per Lugano Response Criteria as assessed by BICR, To evaluate the safety and tolerability of zilovertamab vedotin;Primary end point(s): Objective Response Rate (ORR) per Lugano Response Criteria
- Secondary Outcome Measures
Name Time Method Secondary end point(s):Duration of Response (DOR) per Lugano Response Criteria 1;Secondary end point(s):Number of Participants Who Experience an Adverse Event (AE);Secondary end point(s):Number of Participants Who Discontinue Study Treatment Due to an AE